Exclusive: Oppenheimer Says Insys-Mallinckrodt Merger Not Any More Likely Than It Was 4 Months Ago
Shares of Insys were trading higher by more than 6 percent Wednesday.
Speaking to Benzinga on Wednesday, Oppenheimer analyst Akiva Felt said that progression of rumor between the two companies is "still stagnant," but he added that it "fits into" Mallinckrodt's strategy.
The analyst also added that he "doesn't know why it would be more likely now versus four months ago."
Finally, when asked if a consolidation is expected between large biotech companies and smaller cannabis companies, Felt suggested that analysts are "talking down" on M&A chatter of that magnitude.
Latest Ratings for INSY
|Apr 2016||Janney Capital||Initiates Coverage on||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.